Salinomycin co-treatment enhances tamoxifen cytotoxicity in luminal A breast tumor cells by facilitating lysosomal degradation of receptor tyrosine kinases

Luminal A breast cancer is the most common breast cancer subtype which is usually treated with selective estrogen receptor modulators (SERMS) like tamoxifen. Nevertheless, one third of estrogen receptor positive breast cancer patients initially do not respond to endocrine therapy and about 40% of lu...

Descripción completa

Detalles Bibliográficos
Autores principales: Sommer, Ann-Katrin, Hermawan, Adam, Mickler, Frauke Martina, Ljepoja, Bojan, Knyazev, Pjotr, Bräuchle, Christoph, Ullrich, Axel, Wagner, Ernst, Roidl, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226596/
https://www.ncbi.nlm.nih.gov/pubmed/27409163
http://dx.doi.org/10.18632/oncotarget.10459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226596/
https://www.ncbi.nlm.nih.gov/pubmed/27409163
http://dx.doi.org/10.18632/oncotarget.10459

Ejemplares similares